| 周美玉,许国发,王泽新,等.杀伤细胞联合化疗治疗中晚期肺癌的临床疗效分析[J].安徽医药,2018,22(11):2137-2140. |
| 杀伤细胞联合化疗治疗中晚期肺癌的临床疗效分析 |
| Efficacy of cytokine-induced killer cells combined with chemotherapy on patients with advanced lung cancer |
| 投稿时间：2016-10-08 |
| DOI： |
| 中文关键词: 细胞因子诱导杀伤细胞 化疗 肺癌 临床疗效 |
| 英文关键词: Cytokine-induced killer cells Chemotherapy Lung cancer Efficacy |
| 基金项目:重庆市涪陵区科技计划项目(FLKJ2011ABB2058) |
|
| 摘要点击次数: 2534 |
| 全文下载次数: 821 |
| 中文摘要: |
| 目的 观察细胞因子诱导的杀伤细胞(CIK细胞)联合化疗治疗中晚期肺癌的临床疗效。方法 选择2010年10月至2013年1月经重庆市涪陵中心医院病理活检确诊的120例肺癌患者为研究对象,将其分为治疗组和对照组,每组60例。治疗组给予CIK细胞联合化疗治疗,对照组给予单纯化疗,比较两组患者治疗后免疫功能、B7H4蛋白水平、生活质量(以KPS评分为标准)、生存时间。结果 治疗组治疗后CD3+、CD4+百分比较治疗前提高,差异有统计学意义(t=2.39,P=0.02)。治疗组治疗前后B7H4蛋白水平分别为(61.08±9.52)、(55.86±7.80) μg\5L-1,差异有统计学意义(t=6.34,P=0.00)。治疗组和对照组治疗后患者生活质量分别为88.3%和71.7%,差异有统计学意义(χ2=5.208,P=0.039)；治疗组和对照组中位生存时间分别为20个月和17个月,差异有统计学意义(χ2=7.113,P=0.008)。结论 CIK联合化疗治疗中晚期肺癌患者可能通过降低B7H4蛋白水平,提高了患者免疫功能、生活质量和延长生存时间。 |
| 英文摘要: |
| Objective To observe the clinical efficacy of cytokine-induced killer cells (CIK) combined with chemotherapy for advanced lung cancer.Methods A hundred and twenty patients with advanced lung cancer diagnosed by pathological biopsy in Chongqing Fuling Central Hospital from October 2010 to January 2013 were assigned into two groups,the treatment group (n=60) and the control group (n=60).The treatment group received CIK combined with chemotherapy,while the control group received chemotherapy alone.The immune function,B7H4 protein levels,quality of life (KPS scores as criteria) and median survival time were evaluated and compared between the two groups.Results The percentage of the levels of CD3+and CD4+in the treatment group increased after treatment,which showed statistically significant difference (t=2.39,P=0.02).The levels of B7H4 protein in the treatment group were (61.08±9.52 μg·L-1) before treatment and (55.86±7.80 μg·L-1) after treatment,which showed statistically significant difference (t=6.34,P=0.00).The KPS improvement rate in the treatment group and control group were 88.3% and 71.7%,respectively,which showed statistically significant difference (χ2=5.208,P=0.039).The median survival time of the treatment group was 20 months,which was three months longer than that of the control group,the difference was statistically significant (χ2=7.113,P=0.008).Conclusion CIK combined with chemotherapy for patients with advanced lung cancer may improve immunity,quality of life and prolong survival of the patients by reducing B7H4 protein levels. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
